U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Controlled Substance Act

; .

Author Information and Affiliations

Last Update: March 24, 2023.

Continuing Education Activity

The Controlled Substance Act (CSA) is a statute establishing a federal policy to regulate the manufacturing, distributing, importing/exporting, and using of regulated substances. It lays the framework for the categorization of controlled substances and creates a legal foundation for their regulation. This activity will highlight the categorization schedules, amendments, prescription requirements, and other key factors pertinent for interprofessional team members to understand the legal structure and apply it to their clinical practice.

Objectives:

  • Summarize how the Controlled Substance Act was derived and the needs it met.
  • Review issues of concern with the original Controlled Substance Act and how it was amended thereafter.
  • Explain the controlled substance classification system.
  • Describe the requirements mandated for a proper prescription by an interprofessional team.
Access free multiple choice questions on this topic.

Introduction

Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, commonly known as the Controlled Substance Act (CSA), establishes a federal policy to regulate the manufacturing, distributing, importing/exporting, and use of regulated substances.[1] The CSA was enacted by the 91st United States Congress and signed by President Richard Nixon into law in 1970.[2]

This statute was an effort to combine all previous federal drug laws and allow for federal law enforcement of controlled substances, serving as the legal foundation in the federal fight against drug abuse. Originally the purpose of the CSA was to fulfill the requirements of two international treaties, the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971).[2]

These two treaties had created a classification system in accordance with the scientific and medical findings of public health authorities. Under the two international treaties, the public health authority referenced is the World Health Organization, and under the CSA, it is the Secretary of Health and Human Services (HHS).[2]

Function

Governing Bodies

While the original substances placed under each schedule were created by Congress, the legislation gave power to two federal agencies, the Food and Drug Administration (FDA) and the Drug Enforcement Agency (DEA), to determine the substances added or removed from the classification schedules. The process to remove, add, or change the schedule of a controlled substance can be proposed by the DEA, the Department of HHS, or by petition from an interested party.[3]

Once the DEA collects all relevant data, it requests a scientific and medical evaluation and recommendation, which is prepared by the FDA. Once the DEA receives this information, it evaluates all the data and makes a final proposal. The enforcement and regulation of the CSA also are under the purview of the DEA.[3] To achieve this, the DEA oversees the registration system of who is authorized to manage controlled substances.

Registration

Through the CSA, Congress restricted those allowed to manufacture, import, export, distribute and dispense controlled substances by requiring registration. The US Attorney General provides this registration, which is mandatory for any person or company making or using any controlled substance, as defined by the CSA. Pharmacies can currently register for three years before needing to re-register.[4]

There is a notable exemption in that while a pharmacy itself must register, the pharmacists employed by that pharmacy are exempt from registering as individuals under the CSA.[5] However, individual states may remove these automatic exemptions if they so choose.

Issues of Concern

Amendments

Since its original enactment, the CSA has had many amendments. These amendments have notably included the 2010 Secure and Responsible Drug Disposal Act, allowing pharmacies to create take-back programs for controlled medications, and the 2017 Protecting Patient Access to Emergency Medications Act, including registration for Emergency Medical Services to allow administration of controlled substances.[6]

Another important amendment came in the form of the federal Analogue Act, which treats any substance “substantially similar” to a controlled substance of Schedule I or II as if itself were listed in Schedule I if intended for human consumption. This amendment applies mostly to what is often regarded as designer drugs, an analog of a controlled substance designed to mimic its effects but often avoid detection by standard drug testing.[7]

Employment of Convicted Individuals

The CSA mandates that a person with any felony related to a controlled substance or a person who has had an application for registration denied for cause may not be employed by a pharmacy in a position that will allow access to controlled substances. “For cause” in this case is defined as a DEA registration denied or revoked/surrendered resulting from an investigation regarding an individual’s handling of controlled substances. There is a waiver to this rule should a registrant apply for an exception from an administrator of the DEA, who will collect all relevant information, review, and determine a person’s status.

Reporting Significant Theft or Loss

Under the CSA, any registered dispensary (pharmacy) or manufacturer must immediately report theft or loss of a significant amount of controlled substance to the DEA and the local police.[8] This loss or theft may be reported to the DEA online or on the paper DEA Form 106. The online portal with the form for reporting is on the DEA’s Diversion Control Program website.[9] Failure to report is illegal and punishable by law.

Clinical Significance

Prescription Requirements

To be considered valid, a controlled substance prescription must meet several criteria; it must be issued by a practitioner in the usual course of their practice and be issued for a legitimate medical purpose. If these criteria are not met and the prescription has still been refilled, the person dispensing the medication is subject to penalties for violating the CSA.[8]

The CSA also requires prescribers to include their individual registration number on each controlled substance prescription. A DEA-issued registration number includes nine characters with two letters followed by seven digits. Registration numbers for physicians began with the letters A, B, or C. In contrast, the numbers for physicians’ assistants or nurse practitioners begin with M. The second letter is commonly the first letter of the provider’s last name. As another check for the validity of the registration number, the final seventh digit is equivalent to the last number of the sum of digits 1,3, and 5, followed by digits 2, 4, and 6 multiplied by 2.[9]

If there is incorrect or missing information on a prescription for a controlled substance, and if it is from Schedule III, IV, or V, a pharmacist can change or fill in certain items with authorization from the provider. Pharmacists can change the quantity, strength, form, directions for use, and issue date to meet these requirements. The information that can never be changed is the patient’s name, the controlled substance prescribed, and the prescriber’s signature.[8]

Scheduling System

The cornerstone of the CSA is the classification system by which it regulates controlled substances. In this system, there are five schedules of substance, numbered I-V. The CSA stratifies these based on a substance’s accepted medical use, the potential for abuse/addiction, and harmfulness. Schedule I contained the substances with the most potential for abuse, harm and have no recognized medical uses, while Schedule V has the least dangerous substances with known medical uses. Of note, controlled substance as defined in the Controlled Substance Act means “a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. The term does not include distilled spirits, wine, absinthe, malt beverages, nicotine, or tobacco, as those terms are defined or used in subtitle E of the Internal Revenue Code of 1986”. This exemption for alcohol and tobacco is important as they are the most widely used drugs in the United States.

Schedule I

Schedule I controlled substances are described as having an unacceptable lack of safety, a high potential for abuse/addiction, and currently have no accepted medical use in treatment in the United States. No prescriptions may be written for Schedule I substances. Drugs listed in this schedule include diacetylmorphine (heroin), psychedelic drugs such as psilocybin, MDMA, lysergic acid diethylamide (LSD), and marijuana.[10] The most contested controlled substance of this category is marijuana, which has been petitioned and denied reclassification (2001) despite many states making marijuana legal and the decriminalization in other states.[11]

Schedule II

Schedule II controlled substances are defined as having high potential for abuse and dependence, with significant risk to patient safety, and have medical use in the United States. Schedule II substances require an original prescription, either written or electronically transmitted from a practitioner. No oral prescriptions are allowed except in emergency situations.[12] An emergency situation as defined by the CSA includes immediate administration of the controlled substance is necessary for proper treatment, there are no appropriate alternative treatments, and a written prescription to the pharmacist is not reasonably possible for the prescriber.

Partial filling of a Schedule II controlled substance is permitted if the pharmacist cannot supply the full amount of a written or emergency oral prescription so long as the amount dispensed is properly documented, and the rest can be filled within 72 hours.[12] A new prescription is required if the rest of the prescription is not filled within the 72-hour window. The exception to this comes in the form of terminally ill patients or patients in long-term care facilities (LTCF). Schedule II prescriptions can be partially filled for these patients, but they must contain the notation “LTCF patient” or “terminally ill.” Otherwise, that prescription will violate the CSA. For each partial filling in these cases, the pharmacist must record the amount dispensed such that the sum of the partial fills will never exceed the total quantity of the prescription. The total of these partial prescriptions to patients in LTCF or terminally ill patients cannot exceed 60 days from the prescription date.[12]

For Schedule II substances, pre-dated and post-dated prescriptions pose a significant problem. Per CSA guidelines, the prescription for a controlled substance must be signed and dated on the date issued. This poses significant issues for some patients, for whom obtaining new prescriptions monthly is very difficult. Thus in 2006, an amendment was issued that multiple prescriptions allowing up to a 90-day supply of Schedule II substances may be issued if a practitioner determines there is a legitimate medical purpose, that the earliest date to be filled is written on each subsequent prescription, and that the length or amount of this prescription does not create undue risk of diversion or abuse.[10][12]

Schedule II controlled substances include amphetamines, many barbiturates, cocaine (used as a local anesthetic or to stop severe epistaxis), many opioids (fentanyl, hydromorphone, morphine, oxycodone, etc.), and phencyclidine, also known as PCP (used as a veterinary anesthetic).

Schedule III

Schedule III controlled substances are defined as having moderate potential for abuse (less than Schedules I or II) with abuse leading to moderate physical dependence and have a currently accepted medical use in the United States. Schedule III substances may be filled with a written, electronic, or oral prescription and can be filled/refilled up to six months after the date of issue and may be refilled up to five times before requiring renewal by the practitioner.

The CSA allows for the transfer of prescriptions for Schedule III, IV, and V controlled substances between pharmacies one-time, state-law permitting.[10] The exception to this rule is if the pharmacies share an online, real-time database, then the prescription may be transferred between pharmacies up to the maximum number of refills.[13]

Controlled substances within Schedule III include ketamine (a shorter-acting, safer version of PCP now used for veterinary and pediatric anesthesia), anabolic steroids, and buprenorphine.

Schedule IV

Schedule IV substances are defined as having a low potential for abuse, may lead to limited physical/psychological dependence, and has medical uses currently accepted in the United States. Control measures for substances in Schedule IV may be refilled up to five times in a six-month period.

Schedule IV substances include benzodiazepines (alprazolam, diazepam, clonazepam, etc.), zolpidem, and tramadol.

Schedule V

The substances with the least relative potential for abuse and physical or psychological dependence and with current medical uses in the United States are in Schedule V. These include cough suppressants containing codeine, pregabalin, and lacosamide.[10][13]

Other Issues

Combat Methamphetamine Epidemic Act of 2005

The CSA also allows for the regulation of chemicals that are precursors to controlled substances. The Combat Methamphetamine Epidemic Act was passed as an amendment to the Patriot Act renewal, which placed comprehensive restrictions on the sale of medications containing precursor chemicals to amphetamines/methamphetamine. 

This new law created a CSA category of “Scheduled Listed Chemical Products,” effectively reclassifying all products containing ephedrine and pseudoephedrine. Products containing these ingredients are now subject to sales restrictions and record-keeping requirements. The law limits the purchase of products with pseudoephedrine to no more than 3.6 grams per day per purchase and no more than 9 grams in total in a month, as of April 2006.[14] Violations of this law can be charged as a misdemeanor.

Enhancing Healthcare Team Outcomes

The entire health care team, including clinicians, nurses, pharmacists, and pharmacy techs, form a network of checks and balances, all looking to ensure the safety of patients regarding controlled substances that are prescribed and dispensed. A team-centered approach to identifying risk factors, monitoring pain symptoms, and thoroughly assessing patients for chronic pain is the ideal way to limit complications.

The team approach can include evaluating pain symptoms by primary providers, including multi-disciplinary pain modalities (including physical/occupational therapy, recreational therapy, and cognitive behavioral therapy), evaluation of medication regimen by pharmacists, and inclusion of pain medicine specialists. Providers (physicians, physicians' assistants, and nurse practitioners), nurses, and pharmacists can also monitor for adverse effects of controlled substances.

Interprofessional communication between all these interprofessional team members can provide care coordination for optimal management of pain, especially regarding controlled substances. [Level 2]

Review Questions

References

1.
Gabay M. The federal controlled substances act: schedules and pharmacy registration. Hosp Pharm. 2013 Jun;48(6):473-4. [PMC free article: PMC3839489] [PubMed: 24421507]
2.
McAllister WB. The global political economy of scheduling: the international-historical context of the Controlled Substances Act. Drug Alcohol Depend. 2004 Oct 05;76(1):3-8. [PubMed: 15380283]
3.
Drug Enforcement Administration, Department of Justice. Controlled Substances Quotas. Final rule. Fed Regist. 2018 Jul 16;83(136):32784-90. [PubMed: 30020581]
4.
Drug Enforcement Administration (DEA), Justice. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments. Fed Regist. 2002 Aug 09;67(154):51987-52007. [PubMed: 12194173]
5.
Drug Enforcement Administration (DEA), Department of Justice. Clarification of registration requirements for individual practitioners. Final rule. Fed Regist. 2006 Dec 01;71(231):69478-80. [PubMed: 17171847]
6.
Drug Enforcement Administration (DEA), Department of Justice. Disposal of controlled substances. Final rule. Fed Regist. 2014 Sep 09;79(174):53519-70. [PubMed: 25233531]
7.
Bonson KR, Dalton T, Chiapperino D. Scheduling synthetic cathinone substances under the Controlled Substances Act. Psychopharmacology (Berl). 2019 Mar;236(3):845-860. [PubMed: 30969348]
8.
Gabay M. Federal controlled substances act: dispensing requirements, electronic prescriptions, and fraudulent prescriptions. Hosp Pharm. 2014 Mar;49(3):244-6. [PMC free article: PMC3971109] [PubMed: 24715743]
9.
Drug Enforcement Administration (DEA), Department of Justice. Controlled substances and List I chemical registration and reregistration fees. Final rule. Fed Regist. 2012 Mar 15;77(51):15234-50. [PubMed: 22420065]
10.
Lopez MJ, Preuss CV, Tadi P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Drug Enforcement Administration Drug Scheduling. [PubMed: 32491358]
11.
Alharbi YN. Current legal status of medical marijuana and cannabidiol in the United States. Epilepsy Behav. 2020 Nov;112:107452. [PubMed: 32956945]
12.
Drug Enforcement Administration Department of Justice. Dispensing controlled substances for the treatment of pain issuance of multiple prescriptions for schedule II controlled substances. J Pain Palliat Care Pharmacother. 2007;21(2):75-88. [PubMed: 17844732]
13.
Kenny BJ, Preuss CV, Zito PM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 26, 2023. Controlled Substance Schedules. [PubMed: 30860707]
14.
Luckower T. Follow-up on the Combat Methamphetamine Epidemic Act of 2005: review of oral decongestants. J Am Pharm Assoc (2003). 2007 Jan-Feb;47(1):4-5, 8. [PubMed: 17338467]

Disclosure: Nicole Ortiz declares no relevant financial relationships with ineligible companies.

Disclosure: Charles Preuss declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK574544PMID: 34662058

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...